A press release from Dr. Sidney Wolfe, director of the Health Research Group for the organization Public Citizen, praises a study published in the journal Diabetes that links a class of diabetes drugs including Byetta and Januvia with pancreatic cancer risk.
Researchers at the University of California, Los Angeles, and the University of Florida, conducted the study. They found increased precancerous changes such as dysplasia in the pancreases of diabetic patients ...
continue reading...
A new study by researchers at the University of California, Los Angeles, adds to growing evidence that a class of diabetes drugs including Merck’s Januvia and Bristol-Myers Squibb’s Byetta carries a risk of pancreatic cancer.
A Bloomberg story says the researchers noted “marked” cell proliferation and damage — with a potential for evolution into cancer — in people with Type 2 diabetes who were taking that type of drug, called incretin ...
continue reading...
A clinical trial found that the cholesterol drug Tredaptive increased the rate of side effects such as bleeding and infections, while failing in its ostensible purpose of reducing stroke, heart attack, death or the need for surgery in patients with vascular disease.
According to a Bloomberg report, researchers presented the study of 25,673 patients at the American College of Cardiology meeting in San Francisco.
Tredaptive’s manufacturer, Merck, has suffered from other recent ...
continue reading...
A story in the Huffington Post says there’s been an alarming increase in diabetes in recent years. Officials with the U.S. Centers for Disease Control and Prevention project that as many as one in three Americans could have diabetes by 2050 if current trends continue.
According to the article, CDC officials estimate that one in 10 Americans have diabetes now, amounting to about 24 million.
Treatment is available, but some treatments carry ...
continue reading...
A blog post on Forbes deals with Johnson & Johnson’s type 2 diabetes drug Canagliflozin, which is expected to receive FDA approval soon and which the report describes as having “blockbuster potential.”
According to the report, Canagliflozin proved effective at lowering blood glucose levels and causing weight loss in diabetics during clinical trials. But it also showed potentially troubling side effects, in the form of elevated risk for heart problems.
The item ...
continue reading...
Shares of pharmaceutical companies that make newer types of diabetes medication have fallen, following the U.S. Food and Drug Administration’s announcement that the agency is looking into potential health risks, according to a March 14 story in Bloomberg.
Among those drugs are Merck’s Januvia and Bristol-Myers Squibb’s Byetta.
The U.S. Food and Drug Administration has said the agency is seeking more information about recent findings linking the drugs to an increased risk ...
continue reading...
